Reditux Rituximab 500 mg Injection is administered for treatment of various autoimmune disorders and certain types of cancers. Administered via intravenous route, it is known to have 100% bioavailability with elimination half-life of around 30 to 400 hours depending upon dose. This injection comprises rituximab as active chemical having molecular weight of 143859.7 g/mol. It is known to work by binding to CD20 protein and exerting its curative effects. Reditux Rituximab 500 mg Injection is also suitable to be prescribed for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis conditions.